POPULARITY
50 episodes with co editor
12 episodes with co editor
27 episodes with co editor
8 episodes with co editor
7 episodes with co editor
5 episodes with co editor
3 episodes with co editor
4 episodes with co editor
10 episodes with co editor
Palestinian analyst Mouin Rabbani and Iranian analyst Trita Parsi talks about the latest developments in the Middle East and whether Trump is finally sidelining Israel when it comes to Gaza, Yemen and Iran. Then Vijay Prashad discusses tensions between India and Pakistan and the 80th anniversary of the defeat of fascism. For the full discussion, please join us on Patreon at - https://www.patreon.com/posts/patreon-full-128900208 Mouin Rabbani is a researcher, analyst, and commentator specialising in Palestinian affairs, the Arab-Israeli conflict, and the contemporary Middle East. He has among other positions previously served as Principal Political Affairs Officer with the Office of the UN Special Envoy for Syria, Head of Middle East with the Martti Ahtisaari Peace Foundation, and Senior Middle East Analyst and Special Advisor on Israel-Palestine with the International Crisis Group. Rabbani is Co-Editor of Jadaliyya, and a Contributing Editor of Middle East Report. Trita Parsi is the executive vice president of the Quincy Institute. He is the award-winning author of "Losing an Enemy: Obama, Iran, and the Triumph of Diplomacy" and "Treacherous Alliance: The Secret Dealings of Israel, Iran, and the United States" and the 2010 recipient of the Grawemeyer Award for Ideas Improving World Order. Vijay Prashad is an Indian historian and journalist. He is the author of forty books, including Washington Bullets, Red Star Over the Third World, The Darker Nations: A People's History of the Third World, The Poorer Nations: A Possible History of the Global South, and The Withdrawal: Iraq, Libya, Afghanistan, and the Fragility of U.S. Power, written with Noam Chomsky. Vijay is the executive director of Tricontinental: Institute for Social Research, the chief correspondent for Globetrotter, and the chief editor of LeftWord Books (New Delhi). He also appeared in the films Shadow World (2016) and Two Meetings (2017). Link to the book 'On The Pleasures of Living in Gaza' - https://orbooks.com/catalog/on-the-pleasures-of-living-in-gaza/ ***Please support The Katie Halper Show *** For bonus content, exclusive interviews, to support independent media & to help make this program possible, please join us on Patreon - https://www.patreon.com/thekatiehalpershow Get your Katie Halper Show Merch here! https://katiehalper.myspreadshop.com/all Follow Katie on Twitter: https://x.com/kthalps Follow Katie on Instagram https://www.instagram.com/kthalps/
Dr. Aly Cohen discusses How to Protect Yourself from Toxic Chemicals with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.] Podcast Highlights The Impact of Everyday Toxins with Dr. Aly Cohen In this episode of the Rational Wellness Podcast, host Dr. Ben Weitz discusses the dangers of everyday toxins with Dr. Aly Cohen, founder and medical director of Integrative Rheumatology Associates and The Smart Human. Dr. Cohen shares her personal journey, which was catalyzed by her pet retriever's illness, leading her to explore how environmental toxins affect both pets and humans. They delve into specific toxins such as BPA and perfluoroalkyl substances (PFAS), their effects on the immune system, and methods to reduce exposure, including dietary choices and lifestyle adjustments. Dr. Cohen introduces her 'Four A's' strategy to assess, avoid, swap, and add healthy practices, offering practical solutions for managing and mitigating these toxins in everyday life. 00:29 Meet Dr. Aly Cohen: Expert on Toxins 01:50 The Story of Truxton: A Personal Journey 03:54 Uncovering the Dangers of Everyday Chemicals 07:54 Practical Solutions for Reducing Toxin Exposure 11:08 The Science Behind Toxins and Autoimmune Diseases 18:17 Water Quality and Food Choices 21:34 Personal Care Products and Household Cleaners 22:34 Introducing the Apollo Wearable 23:27 Sleep and Focus Benefits 24:07 Impact of Toxins on Autoimmune Conditions 25:01 The Four A's of Reducing Toxins 27:16 Immune Disrupting Chemicals 30:59 Endocrine Disrupting Chemicals 32:41 Detox Strategies and Supplements 38:45 Mediterranean Diet and Quality Food 41:27 Conclusion and Resources _______________________________________________________________________________________________________ Dr. Aly Cohen is an Integrative Rheumatologist and the Founder & Medical Director of Integrative Associates and also the Founder and Medical Director of The Smart Human LLC. She is a Co-Editor and contributor to Integrative Environmental Medicine, Co-author of Non-Toxic: Guide to Living Healthy in a Chemical World, and the new book, Detoxify: The Everyday Toxins Harming Your Immune system and How to Defend Against Them. Her websites are AlyCohenMD.com and TheSmartHuman.com Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure. Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.
In this episode of Enterprise.ing, Angela Sandler, Co-Owner & Co-Editor of The Scout Guide St. Louis and Xplor, shares how strategic collaboration and experiential marketing have powered her entrepreneurial journey. From launching a tech platform for kids to amplifying brands through local partnerships and high-touch campaigns, Angela emphasizes the importance of relationship-building, adaptability and mindset. “Failure is not easy for me… I had to really shift my mindset with that. I had never really been taught that there are no failures, there's just learned lessons.” The views expressed by Enterprise.ing® presenters or guests are those of the presenter or guest and not, necessarily, of Enterprise Bank & Trust or its affiliates. All content, related materials and third party website links are for informational purposes only and do not constitute an endorsement by Enterprise Bank & Trust. Enterprise Bank & Trust does not make any warranty, express or implied, including warranties of merchantability and fitness for a particular purpose, and specifically disclaims any legal liability or responsibility for accuracy, completeness or usefulness of any information presented. Enterprise Bank & Trust is not under any obligation to update or correct any materials or content provided in connection with this podcast. All statements and opinions are subject to change without notice. ©2025 Enterprise Bank & Trust. All Rights Reserved.
Science is rediscovering the medicinal potential of things like magic mushrooms for treatments. UCC recently held a research day about this, and Oliver Davis, Professor of French at UCC and former Co-Editor of the Frontiers in Psychology series joins Tom Dunne to discuss…
Science is rediscovering the medicinal potential of things like magic mushrooms for treatments. UCC recently held a research day about this, and Oliver Davis, Professor of French at UCC and former Co-Editor of the Frontiers in Psychology series joins Tom Dunne to discuss…
Edward G. Dudley, Ph.D. is the Director of the E. coli Reference Center and a Professor of Food Science at the Pennsylvania State University. He has a broad background in molecular biology, physiology, and foodborne bacteria genomics, with expertise in both beneficial and pathogenic species. His current research program focuses on factors that drive the virulence of Escherichia coli O157:H7 and the development of DNA sequence-based methods for tracking pathogen spread during foodborne illness outbreaks, including wastewater monitoring. Dr. Dudley is a past Chair of the Food Microbiology Division of the American Society of Microbiology (ASM), the Food Microbiology Representative to ASM's Council of Microbial Sciences, and a previous member of ASM's Microbe Program Committee. In 2019, he was appointed an ASM Distinguished Lecturer and Co-Editor of the Evolution and Genomics domain for ASM's online journal, EcoSal Plus. He was also elected to the American Academy of Microbiology in 2023. Dr. Dudley holds a Ph.D. in Bacteriology and an M.S. degree in Food Science, both from the University of Wisconsin–Madison. In this episode of Food Safety Matters, we speak with Dr. Dudley [35:17] about: A study conducted by Dr. Dudley's lab that investigated the usefulness of wastewater monitoring for surveillance of foodborne Salmonella illnesses How whole genome sequencing (WGS) was used to link Salmonella isolates from wastewater systems in central Pennsylvania to an existing salmonellosis outbreak The significance of discovering the rare S. Baildon serotype in the wastewater samples How wastewater monitoring activities could fill gaps created when foodborne illnesses go underreported by infected people, as well as the potential limitations of wastewater monitoring for foodborne illness surveillance Other foodborne pathogens besides Salmonella that could be surveilled via wastewater monitoring Apart from the Salmonella wastewater monitoring study, various research projects carried out by Dr. Dudley's lab related to E. coli. Before we speak to Dr. Dudley, we also hear from Patrick Schneider [25:37], Vice President of Operations and Engineering (Chlorine Dioxide) at CDG Environmental LLC. In his interview, he discusses the usefulness of chlorine dioxide for food plant sanitation, and what makes CDG Solution 3000TM the “gold standard in chlorine dioxide solutions.” Prior to joining CDG Environmental, Mr. Schneider spent 35 years holding various global roles in the oil and gas industry. He holds a B.S. degree in Petroleum Engineering from Penn State University. News and Resources News FDA Delays FSMA 204 Traceability Rule Compliance Date by 30 Months [4:02]FDA Launches ‘Operation Stork Speed' to Improve Infant Formula Safety, Including Contaminant Testing [11:08]Thousands More Layoffs Coming to FDA, CDC as HHS Announces Major Restructuring [12:06]Microplastics Increase Antibiotic Resistance of E. coli, Aid Biofilm Formation, Study Shows [18:12]Proposed Rule Would Require Mandatory Labeling on Alcoholic Beverages for Big 9 Food Allergens [22:35]Trump Admin Nominates CDC Acting Director Dr. Susan Monarez as Agency's Next Director [23:10]Boar's Head Appoints Natalie Dyenson as Chief Food Safety Officer [24:09] Resources Get 20 percent off your 2025 Food Safety Summit registration with code “FSMatters20” Wastewater Monitoring Can Aid Foodborne Illness Surveillance, Study Shows Wastewater Surveillance Useful for Norovirus Outbreak Detection Presenting Sponsor: CDG Environmental Visit CDG Environmental at Booth #333 at the 2025 Food Safety Summit! We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
The founder and Co-Editor of AIR MAIl, Graydon Carter, has written his long-awaited memoir, entitled When the Going Was Good: An Editor's Adventures During the Last Golden Age of Magazines, and we're excited to have him join us to talk about his book, the enduring magic of New York, and more. Then, for years Danny Elfman was one of the most sought-after composers in Hollywood, writing scores for movies such as Beetlejuice, Batman, and The Nightmare Before Christmas. But now his reputation is in tatters as he faces accusations of sexual harassment. Jacob Bernstein joins us to discuss the story that has riveted—and perplexed—Hollywood.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
College film productions already require students to push their abilities to the max and plan far into the future, and even then these passion projects seem to invite all kinds of disasters. Just when they thought everything was going as planned, they were confronted with fire alarms, scheduling setbacks, screaming children…and worst of all, important life lessons! We're here to bring you these Tales From the Set: allowing us to find out exactly where everything went wrong, and discover how a few talented students and alumni were still able to make it go right. Lena Beck - Co-Host, Co-ProducerCandice Leach - Co-Host, Co-ProducerEvan Schack - Co-Host, Co-Editor, RecordistRuby Zuckerman - Co-Host, Co-EditorKyle Broner - Guest Hannah Raizman - Guest Nick del Bianco - Guest Quinn DiPalo - Guest
Discover effective survival strategies under authoritarianism in "Beautiful Solutions: A Toolbox for Liberation," featuring insights from global contributors and activists.This show is made possible by you! To become a sustaining member go to https://LauraFlanders.org/donate Thank you for your continued support!How do people survive authoritarianism? With harsher policing, market chaos, mass layoffs and healthcare cuts, Americans are fearing the worst under Donald Trump and Elon Musk, and many are seeking effective survival tools. Arriving just on time, “Beautiful Solutions: A Toolbox for Liberation” was published last year by OR Books. It's packed with collective wisdom for surviving, and in so doing, creating a more just, equitable society. With over 70 contributions from the Americas, Africa, Asia and Indigenous peoples around the world, change is everywhere, it can start anywhere, and as “Beautiful Solutions” reminds us, “our problems are global and interconnected, and our solutions must be too.” To expand on some of the models in the book, Laura Flanders is joined by one of the co-editors Eli Feghali, former director of the New Economy Coalition, and contributor Nikki Marín Baena, co-founder and co-director at Siembra NC, a Latino base building and political organization in North Carolina. Lauren Hudson co-hosts. Hudson is a cooperative and Solidarity Economy organizer and researcher and teaches at the CUNY School of Labor and Urban Studies.“. . . How do we dream our big dreams about not just what we're fighting against, but what we're fighting for, and really hold onto those and also understand that the little projects and the little connections that we make with each other, those are the only things that can become those big dreams.” - Nikki Marín Baena“The only thing that I feel some fear about in this moment is that maybe some of us will give up ground that we don't need to give up out of anticipatory fear of what might happen . . . That's not to say that the risks aren't real, that's not to say that the plans that are being telegraphed and the news aren't real, but it's to say that we should not let go of what we fought for until we absolutely have to . . . We just have to trust each other and trust ourselves.” - Eli Feghali“I have to think as an educator . . . how do we teach this moment? . . . I think what [my students] will say is this was a rupture, and it was a rupture that forced many of us back into some corners, but it was also an invitation to participate in the world in a different way.” - Lauren HudsonGuests:•. Eli Feghali, Co-Editor, Beautiful Solutions; Former Co-Director, New Economy Coalition•. Nikki Marín Baena, Co-Director, Siembra NC•. Lauren Hudson, Organizer & Researcher, Cooperative and Solidarity Economy Watch the episode cut airing on PBS stations across the country at our YouTube channelSubscribe to episode notes via Patreon *Recommended book:“Beautiful Solutions: A Toolbox for Liberation” by Elandria Williams, Rachel Plattus, Eli Feghali and Nathan Schneider, *Get the Book(*Bookshop is an online bookstore with a mission to financially support local, independent bookstores. The LF Show is an affiliate of bookshop.org and will receive a small commission if you click through and make a purchase.)Related Laura Flanders Show Episodes:• Cooperation vs Authoritarianism in Spain, Watch / Listen• Taking Power vs Making Power: A Special Report from Greece, Watch / Listen • Armed with Art: Taking Down the Wall of Whiteness, Watch / ListenRelated Articles and Resources:• Beautiful Trouble, Sister Project to Beautiful Solutions Learn More• Pandas And The Informal Economy of Mexico, by Medium• Prepare to Oppose Trump's Immigrant Purge, by Nikki Marín Baena, November 22, 2024, Progressive Laura Flanders and Friends Crew: Laura Flanders, along with Sabrina Artel, Jeremiah Cothren, Veronica Delgado, Janet Hernandez, Jeannie Hopper, Sarah Miller, Nat Needham, David Neuman, and Rory O'Conner. FOLLOW Laura Flanders and FriendsInstagram: https://www.instagram.com/lauraflandersandfriends/Blueky: https://bsky.app/profile/lfandfriends.bsky.socialFacebook: https://www.facebook.com/LauraFlandersAndFriends/Tiktok: https://www.tiktok.com/@lauraflandersandfriendsYouTube: https://www.youtube.com/channel/UCFLRxVeYcB1H7DbuYZQG-lgLinkedin: https://www.linkedin.com/company/lauraflandersandfriendsPatreon: https://www.patreon.com/lauraflandersandfriendsACCESSIBILITY - The broadcast edition of this episode is available with closed captioned by clicking here for our YouTube Channel
Professor Dagmawi Woubshet, co-editor of "Ethiopia: Modern Nation- Ancient Roots" book and Toni Morrison Senior Fellow, speaks about the book launch at the Africa Institute on March 6 and the rich culture and history of Ethiopia, on the Morning Majlis show.
Josh Ethier is a film editor who has become a household name in horror. Josh is the editing force behind such films as: Contracted, Some Kind of Hate, We are Still Here, Mayhem, Leatherface, Bliss, VFW, Orphan First Kill, Christmas Bloody Christmas, The Seventh Day, Gretel and Hansel, Don't Breathe and most recently Companion which he edited alongside Brett Bachman.In this episode, Josh gets into his career history, editing process, collaborations with filmmakers like Joe Begos and Osgood Perkins and the story behind the recently released Companion, which is one of my favorite horror movies in a long time. This is a really insightful conversation that I really enjoyed and think you will as well. Please welcome, Josh Ethier!Here are some key takeaways from this conversation with JoshLook for the Note Behind the NoteAudience feedback can be a double-edged sword—sometimes useful, sometimes misleading. Josh learned early on from Stuart Gordon (Re-Animator) that feedback isn't about taking every note literally but understanding the note behind the note which requires deeper analysis.For instance, on Companion, early test screenings showed that one character was getting lower audience scores. Instead of softening the character, they leaned into the audience's dislike and committed to it—embracing the audience's reaction rather than trying to cater to feedback. As a result, the character actually scored higher in later tests.Editing is a “Four-Month Conversation” Between Director and EditorThe relationship between an editor and a director is one of the most intimate creative partnerships in filmmaking. Josh emphasizes that the strongest director-editor teams are built on genuine relationships, which is why socializing and getting to know each other outside of the work is just as important as the technical process.The best collaborations happen when an editor and director truly understand each other's creative DNA—the movies that inspire them, their sense of humor, their artistic instincts, and how they think about storytelling. The editing room isn't just where cuts are made; it's where creative risks are taken, where directors feel safe enough to experiment, and where an editor helps guide them toward their best possible work.The more an editor and director understand each other, the better they can anticipate each other's needs, develop a shorthand, challenge each other in the right ways, and ultimately make the movie stronger.Immerse Yourself in QualityJosh believes that editors—and all filmmakers—should obsessively watch and absorb great films. But instead of overanalyzing or attempting to reverse-engineer their greatness, the key is exposure. Some films are great because they have an innate rhythm, a unique DNA that can't simply be replicated. Rather than trying to deconstruct and apply a formula, internalize their essence. Understand what great filmmaking feels like, so when it comes time to shape your own work, you instinctively recognize when something is working—and when it's not. This is also a common piece of creative advice given by Rick Rubin, and I highly recommend his book The Creative Act.SHOW NOTESMovies DiscussedCompanion (2024)Almost Human (2013)Contracted (2013)Gretel & Hansel (2020)We Are Still Here (2015)First Blood (1982)Jaws (1975)Seven (1995)Looper (2012)Books & ResourcesIn the Blink of an Eye – Walter MurchThe Conversations: Walter Murch and the Art of Editing Film – Michael OndaatjeEasy Riders, Raging Bulls – Peter...
Books of Mana is a new book edited by Jacinta Ruru (Raukawa, Ngāti Ranginui), Angela Wanhalla (Kāi Tahu) and Jeanette Wikaira (Ngāti Pukenga, Ngāti Tamaterā, Ngāpuhi) which released earlier this week. It is the first of its kind in the world to celebrate non-fiction indigenous writing – exploring 200 years of Māori print legacies. In examining the ways 180 selected books have enriched lives and helped to foster understanding of the Māori experience, both at home in Aotearoa and internationally, the book is a clear vision of influence, excellence and diversity of Māori writing. Sofia spoke with co-editor and Distinguished Professor of Law at the University of Otago, Jacinta Ruru, about Books of Mana.
Discusses citizen or participatory science, including its benefits and key ethical issues. Our guest today is Lisa Rasmussen who is a Professor in the Department of Philosophy at the University of North Carolina Charlotte and Editor-in-Chief of the journal Accountability in Research. Lisa has been a principal investigator or co-principal investigator on over $1 million in National Science Foundation awards and serves as a Co-Editor of the book series Philosophy and Medicine and an Associate Editor of the publication Citizen Science: Theory and Practice. Additional resources: Association for the Advancement of Participatory Sciences: https://participatorysciences.org/ Citizen Science: Theory and Practice: https://theoryandpractice.citizenscienceassociation.org/ Citizen Science: How Ordinary People are Changing the Face of Discovery: https://scistarter.com/cooper SciStarter: https://scistarter.org/
Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about the left freaking out over a call Justice Alito made to Donald Trump, and Senators Dick Durbin and Sheldon Whitehouse’s “ethics report” on Justices Alito and Thomas. For more coverage on the issues that matter to you, visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
1/9/25 Hour 3 Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about the left freaking out over a call Justice Alito made to Donald Trump, and Senators Dick Durbin and Sheldon Whitehouse’s “ethics report” on Justice Alito and Thomas. The Laken Riley Act clears the Senate’s first vote 84-9. Vince speaks with John Konrad, CEO of G-Captain, former drillship captain, and author of Fire On The Horizon” about how California has utterly failed to use ocean water in defending from wildfires. The current ICE director admits that Joe Biden failed on border security. For more coverage on the issues that matter to you, visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
About two years ago, we released a podcast with Dr. Thomas Wadden of the University of Pennsylvania describing work on a new generation of medications to treat diabetes and obesity. They were really taking the field by storm. Since then, much more is known since many additional studies have been published and so many people have been using the drugs. So many, in fact, the market value of the Danish company, Novo Nordisk, one of the two major companies selling the drugs, has gone up. It is now greater than the entire budget of the country of Denmark. This single company is responsible for about half of Denmark's economic expansion this year. So, a lot of people are now taking the drugs and this is a great time for an update on the drugs. And we're fortunate to have two of the world's leading experts join us: Dr. Wadden, Professor of Psychology and Psychiatry at the University of Pennsylvania School of Medicine and the inaugural Albert J. Stunkard Professor of Psychiatry at Penn. Joining us as well as Dr. Robert Kushner, a physician and professor of medicine at Northwestern University and a pioneer in testing treatments for obesity. Interview Summary Tom, you and I were colleagues at Penn decades ago. And I got frustrated the treatments for obesity didn't work very well. People tended to regain the weight. And I turned my attention to prevention and policy. But you hung in there and I admired you for that patience and persistence. And Bob, the same for you. You worked on this tenacious problem for many years. But for both of you, your patience has been rewarded with what seems to me to be a seismic shift in the way obesity and diabetes can be treated. Tom, I'll begin with you. Is this as big of a deal as it seems to me? Well, I think it is as big of a deal as it seems to you. These medications have had a huge impact on improving the treatment of type 2 diabetes, but particularly the management of obesity. With older medications, patients lost about 7 percent of their starting weight. If you weighed 200 pounds, you'd lose about 15 pounds. That was also true of our best diet and exercise programs. You would lose about 7 percent on those programs with rigorous effort. But with the new medications, patients are now losing about 15 to 20 percent of their starting body weight at approximately one year. And that's a 30-to-40-pound loss for a person who started at 200 pounds. And with these larger weight losses, we get larger improvements in health in terms of complications of obesity. So, to quote a good friend of mine, Bob Kushner, these medications have been a real game changer. Thanks for putting that in perspective. I mean, we're talking about not just little incremental changes in what treatments can produce, which is what we've seen for years. But just orders of magnitude of change, which is really nice to see. So, Bob what are these medications that we're talking about? What are the names of the drugs and how do they work? Well, Kelly, this transformation of obesity really came about by finding the target that is really highly effective for obesity. It's called the gut brain axis. And when it comes to the gut it's starting off with a naturally occurring gut hormone called GLP 1. I think everyone in the country's heard of GLP 1. It's released after we eat, and it helps the pancreas produce insulin, slows the stomach release of food, and reduces appetite. And that's where the obesity story comes in. So pharmaceutical companies have taken this hormone and synthesized it, something similar to GLP 1. It mimics the action of GLP 1. So, you could actually take it and give it back and have it injected so it augments or highlights this hormonal effect. Now, that same process of mimicking a hormone is used for another gut hormone called GIP that also reduces appetite. These two hormones are the backbone of the currently available medication. There's two on the market. One is called Semaglutide. That's a GLP 1 analog. Trade name is Wegovy. Now, it's also marketed for diabetes. Tom talked about how it is used for diabetes and increases insulin. That trade name is Ozempic. That's also familiar with everyone around the country. The other one that combined GLP 1 and GIP, these two gut hormones, so it's a dual agonist, the trade name for obesity is called Zep Bound, and the same compound for diabetes is called Mounjaro. These are terms that are becoming familiar, I think, to everyone in the country. Tom mentioned some about the, how much weight people lose on these drugs, but what sort of medical changes occur? Just to reiterate what Tom said, I'll say it in another way. For Semaglutide one third of individuals are losing 20 percent of their body weight in these trials. For Tirzepatide, it even outpaces that. And I got a third of individuals losing a quarter of their body weight. These are unheard of weight losses. And with these weight losses and these independent effects from weight, what we're seeing in the trials and in the clinic is that blood pressure goes down, blood sugar goes down, blood fats like triglyceride go down, inflammation in the body goes down, because we marked that with CRP, as well as improvement in quality of life, which we'll probably get to. But really interesting stuff is coming out over the past year or two or so, that it is improving the function of people living with congestive heart failure, a particular form called a preserved ejection fraction. We're seeing improvements in sleep apnea. Think of all the people who are on these CPAP machines every night. We're seeing significant improvements in the symptoms of sleep apnea and the apneic events. And lastly, a SELECT trial came out, that's what it was called, came out last year. Which for the very first time, Kelly, found improvements in cardiovascular disease, like having a heart attack, stroke, or dying of cardiovascular disease in people living with obesity and already have cardiovascular disease. That's called secondary prevention. That, Tom, is the game changer. Bob, I'd like to go back to Tom in a minute but let me ask you one clarifying question about what you just said. That's a remarkable array of biological medical benefits from these drugs. Just incredible. And the question is, are they all attributable to the weight loss or is there something else going on? Like if somebody lost equal amounts of weight by some other means, would these same changes be occurring? Those studies are still going on. It's very good. We're thinking it's a dual effect. It's the profound amount of weight loss, as Tom said. Fifteen to 21 to even 25 percent of average body weight. That is driving a lot of the benefits. But there also appear to be additional effects or weight independent effects that are working outside of that weight. We're seeing improvements in kidney function, improvement in heart disease, blood clotting, inflammation. And those are likely due to the gut hormone effect independent of the weight itself. That still needs to be sorted out. That's called a mitigation analysis where we try to separate out the effects of these drugs. And that work is still underway. Tom, one of the most vexing problems, over the decades that people have been working on treatments for obesity, has been long term results. And I'm curious about how long have people been followed on these drugs now? What are the results? And what was the picture before then? How do what we see now compared to what you saw before? The study that Bob just mentioned, the SELECT trial followed people for four years on Semaglutide. And patients achieve their maximal weight loss at about one year and they lost 10 percent of their weight. And when they were followed up at four years still on treatment, they still maintained a 10 percent weight loss. That 10 percent is smaller than in most of the trials, where it was a 15 percent loss. But Dr. Tim Garvey showed that his patients in a smaller trial lost about 15 percent at one year and while still on medication kept off the full 15 percent. I think part of the reason the weight loss in SELECT were smaller is because the study enrolled a lot of men. Men are losing less weight on this medication than women. But to your question about how these results compare to the results of earlier treatment, well with behavioral treatment, diet, and exercise back in the 70s beyond, people lost this 7 or 8 percent of weight. And then most people on average regain their weight over one to three years. And the same was true of medication. People often stopped these earlier medications after 6 to 12 months, in part because they're frustrated the losses weren't larger. Some people were also worried about the side effects. But the long and short is once you stop taking the medication, people would tend to regain their weight. And some of this weight regain may be attributable to people returning to their prior eating and activity habits. But one of the things we've learned over the past 20 years is that part of the weight regain seems to be attributable to changes in the body's metabolism. And you know that when you lose weight, you're resting metabolic rate, which is the number of calories your body burns at rest to maintain basic bodily functions. Your resting metabolic rate decreases by 10 to 15 percent. But also, your energy expenditure, the calories you burn during exercise decreases. And that may decrease by as much as 20 to 30 percent. So, people are left having to really watch their calories very carefully because of their lower calorie requirements in order to keep off their lost body weight. I think one thing these new drugs may do is to attenuate the drop both in resting metabolic rate and energy expenditure during physical activity. But the long and short of it is that if you stay on these new medications long term, you'll keep off your body weight. And you'll probably keep it off primarily because of improvements in your appetite, so you have less hunger. And as a result, you're eating less food. I'd like to come back to that in a minute. But let me ask a question. If a person loses weight, and then their body starts putting biological pressure on them to regain, how come? You know, it's disadvantageous for their survival and their health to have the excess weight. Why would the body do that? Well, our bodies evolved in an environment of food scarcity, and our physiology evolved to protect us against starvation. First, by allowing us to store body fat, a source of energy when food is not available. And second, the body's capacity to lower its metabolism, or the rate at which calories are burned to maintain these basic functions like body temperature and heart rate. That provided protection against food scarcity. But Kelly, you have described better than anybody else that these ancient genes that regulate energy expenditure and metabolism are now a terrible mismatch for an environment in which food is plentiful, high in calories, and available 24 by 7. The body evolved to protect us from starvation, but not from eating past our calorie needs. And so, it's this mismatch between our evolution and our appetite and our body regulation in the current, what you have called toxic food environment, when you can eat just all the time. I guess you could think about humans evolving over thousands of years and biology adapting to circumstances where food was uncertain and unpredictable. But this modern environment has happened really pretty rapidly and maybe evolution just hasn't had a chance to catch up. We're still existing with those ancient genes that are disadvantageous in this kind of environment. Bob back to the drugs. What are the side effects of the drugs? Kelly, they're primarily gastrointestinal. These are symptoms like nausea, diarrhea, constipation, heartburn, and vomiting. Not great, but they're generally considered mild to moderate, and temporary. And they primarily occur early during the first four to five months when the medications are slowly dose escalated. And we've learned, most importantly, how to mitigate or reduce those side effects to help people stay on the drug. Examples would be your prescriber would slow the dose escalation. So. if you're having some nausea at a particular dose, we wait another month or two. The other, very importantly, is we have found that diet significantly impacts these side effects. When we counsel patients on these medications, along with that comes recommendations for dietary changes, such as reducing fatty food and greasy food. Reducing the amount of food you're consuming. Planning your meals in advance. Keeping well hydrated. And very importantly, do not go out for a celebration or go out to meals on the day that you inject or at least the first two days. Because you're not going to tolerate the drug very well. We use that therapeutically. So, if you want to get control on the weekends, you may want to take your injection on a Friday. However, if weekends are your time out with friends and you want to socialize, don't take it on a Friday. Same thing comes with a personal trainer, by the way. If you're going to have a personal trainer on a Monday where he's going to overwork you, don't take the injection the day before. You'll likely be nauseated, you're not eating, you're not hydrating. So actually, there's a lot that goes into not only when to take the dose and how to take the dose, but how to take it to the best ability to tolerate it. Two questions based on what you said. One is you talked about these are possible side effects, but how common are they? I mean, how many people suffer from these? Well, the trials show about 25 to 45 percent or so of individuals actually say they have these symptoms. And again, we ask them mild, moderate, severe. Most of them are mild to moderate. Some of them linger. However, they really do peak during the dose escalation. So, working with your prescriber during that period of time closely, keeping contact with them on how to reduce those side effects and how you're doing out of medication is extremely important. And the second thing I wanted to ask related to that is I've heard that there's a rare but serious potential side effect around the issue of stomach paralysis. Can you tell us something about that? I mentioned earlier, Kelly, that these medications slow gastric emptying. That's pretty much in everybody. In some individuals who may be predisposed to this, they develop something called ileus, and that's the medical term for gastric paralysis. And that can happen in individuals, let's say who have a scleroderma, who have longstanding diabetes or other gastrointestinal problems where the stomach really stopped peristalsis. In other words, it's moving. That's typically presented by vomiting and really unable to move the food along. We really haven't seen much of that. We looked at the safety data in a SELECT trial that Tom mentioned, which was 17,000 individuals, about 8,000 or so in each group. We really did not see a significant increase in the ileus or what you're talking about in that patient population. Okay, thanks. Tom had alluded to this before, Bob, but I wanted to ask you. How do you think about these medicines? If somebody takes them, and then they stop using the medicines and they gain the weight back. Is that a sign that the medicine works or doesn't work? And is this the kind of a chronic use drug like you might take for blood pressure or cholesterol? That's a great way of setting up for that. And I like to frame it thinking of it as a chronic progressive disease, just like diabetes or hypertension. We know that when you have those conditions, asthma could be another one or inflammatory bowel disease, where you really take a medication long term to keep the disease or condition under control. And we are currently thinking of obesity as a chronic disease with dysfunctional appetite and fat that is deposited in other organs, causing medical problems and so on. If you think of it as a chronic disease, you would naturally start thinking of it, like others, that medication is used long term. However, obesity appeared to be different. And working with patients, they still have this sense 'that's my fault, I know I can do it, I don't want to be on medication for the rest of my life for this.' So, we have our work cut out for us. One thing I can say from the trials, and Tom knows this because he was involved in them. If we suddenly stop the medication, that's how these trials were definitely done, either blindly or not blindly, you suddenly stop the medication, most, if not all of the participants in these trials start to regain weight. However, in a clinical practice, that is not how we work. We don't stop medication suddenly with patients. We go slowly. We down dose the medication. We may change to another medication. We may use intermittent therapy. So that is work that's currently under development. We don't know exactly how to counsel patients regarding long term use of the medications. I think we need to double down on lifestyle modification and counseling that I'm sure Tom is going to get into. This is really work ahead of us, how to maintain medication, who needs to be on it long term, and how do we actually manage patients. Tom, you're the leading expert in the world on lifestyle change in the context of obesity management. I mean, thinking about what people do with their diet, their physical activity, what kind of thinking they have related to the weight loss. And you talked about that just a moment ago. Why can't one just count on the drugs to do their magic and not have to worry about these things? Well, first, I think you can count on the drugs to do a large part of the magic. And you may be surprised to hear me say that. But with our former behavioral treatments of diet and exercise, we spent a lot of time trying to help people identify how many calories they were consuming. And they did that by recording their food intake either in paper and pencil or with an app. And the whole focus of treatment was trying to help people achieve a 500 calorie a day deficit. That took a lot of work. These medications, just by virtue of turning down your appetite and turning down your responsiveness to the food environment, take away the need for a lot of that work, which is a real blessing. But the question that comes up is, okay, people are eating less food. But what are they eating? Do these medications help you eat a healthier diet with more fruits and vegetables, with lean protein? Do you migrate from a high fat, high sugar diet to a Mediterranean diet, or to a DASH like diet? And the answer is, we don't know. But obviously you would like people to migrate to a diet that's going to be healthier for you from a cardiovascular standpoint, from a cancer risk reduction standpoint. One of the principal things that people need to do on these medications is to make sure they get plenty of protein. And so, guidance is that you should have about 1 gram of dietary protein for every kilogram of body weight. If you're somebody who weighs 100 kilograms, you should get 100 grams of protein. And what you're doing is giving people a lot of dietary protein to prevent the loss of bodily protein during rapid weight loss. You did a [00:20:00] lot of research with me back in the 80s on very low-calorie diets, and that was the underpinning of treatment. Give people a lot of dietary protein, prevent the loss of bodily protein. The other side of the equation is just physical activity, and it's a very good question about whether these medications and the weight loss they induce will help people be more physically active. I think that they will. Nonetheless for most people, you need to plan an activity schedule where you adopt new activities, whether it's walking more or going to the gym. And one thing that could be particularly helpful is strength training, because strength training could mitigate some of the loss of muscle mass, which is likely to occur with these medications. So, there's still plenty to learn about what is the optimal lifestyle program, but I think people, if they want to be at optimal health will increase their physical activity and eat a diet of fruits and vegetables, leaner protein, and less ultra processed foods. Well, isn't it true that eating a healthy diet and being physically active have benefits beyond their impact on your ability to lose the weight? You're getting kind of this wonderful double benefit, aren't you? I believe that is true. I think you're going to find that there are independent benefits of being physical activity upon your cardiovascular health. There are independent benefits of the food that you're eating in terms of reducing the risk of heart attack and of cancer, which has become such a hot topic. So, yes how you exercise and what you eat makes a difference, even if you're losing weight. Well, plus there's probably the triple one, if you will, from the psychological benefit of doing those things, that you do those things, you feel virtuous, that helps you adhere better as you go forward, and these things all come together in a nice picture when they're working. Tom, let's talk more about the psychology of these things. You being a psychologist, you've spent a lot of time doing research on this topic. And of course, you've got a lot of clinical experience with people. So as people are losing weight and using these drugs, what do they experience? And I'm thinking particularly about a study you published recently, and Bob was a coauthor on that study that addressed mental health outcomes. What do people experience and what did you find in that study? I think the first things people experience is improvements in their physical function. That you do find as you've lost weight that you've got less pain in your knees, you've got more energy, it's easier to get up the stairs, it's easier to play with the children or the grandchildren. That goes a long way toward making people feel better in terms of their self-efficacy, their agency in the life. Big, big improvement there. And then, unquestionably, people when they're losing a lot of weight tend to feel better about their appearance in some cases. They're happy that they can buy what they consider to be more fashionable clothes. They get compliments from friends. So, all of those things are positive. I'm not sure that weight loss is going to change your personality per se, or change your temperament, but it is going to give you these physical benefits and some psychological benefits with it. We were happy to find in the study you mentioned that was conducted with Bob that when people are taking these medications, they don't appear to be at an increased risk of developing symptoms of depression or symptoms of suicidal ideation. There were some initial reports of concern about that, but the analysis of the randomized trials that we conducted on Semaglutide show that there is no greater likelihood of developing depression or sadness or suicidal ideation on the medication versus the placebo. And then the FDA and the European Medicines Agency have done a full review of all post marketing reports. So, reports coming from doctors and the experience with their patients. And in looking at those data the FDA and the European Medicines Agency have said, we don't find a causal link between these medications and suicidal ideation. With that said, it's still important that if you're somebody who's taking these medications and you start them, and all of a sudden you do feel depressed, or all of a sudden you do have thoughts like, maybe I'd be better off if I weren't alive any longer, you need to talk to your primary care doctor immediately. Because it is always possible somebody's having an idiosyncratic reaction to these medications. It's just as possible the person would have that reaction without being on a medication. You know, that, that can happen. People with overweight and obesity are at higher risk of depression and anxiety disorders. So, it's always going to be hard to tease apart what are the effects of a new medication versus what are just the effects of weight, excess weight, on your mood and wellbeing. You know, you made me think of something as you were just speaking. Some people may experience negative effects during weight loss, but overall, the effects are highly positive and people are feeling good about themselves. They're able to do more things. They fit in better clothes. They're getting good feedback from their environment and people they know. And then, of course, there's all the medical benefit that makes people feel better, both psychologically and physically. Yet there's still such a strong tendency for people to regain weight after they've lost. And it just reinforces the fact that, the point that you made earlier, that there are biological processes at work that govern weight and tendency to regain. And there really is no shame in taking the drug. I mean, if you have high blood pressure, there's no shame in taking the drug. Or high cholesterol or anything else, because there's a biological process going on that puts you at risk. The same thing occurs here, so I hope the de-shaming, obesity in the first place, and diabetes, of course, and then the use of these medications in particular might help more people get the benefits that is available for them. I recommend that people think about their weight as a biologically regulated event. Very much like your body temperature is a biologically regulated event, as is your blood pressure and your heart rate. And I will ask people to realize that there are genetic contributors to your body weight. just as there are to your height. If somebody says, I just feel so bad about being overweight I'll just talk with them about their family history of weight and see that it runs in the family. Then I'll talk to them about their height. Do you feel bad about being six feet tall, to a male? No, that's fine. Well, that that's not based upon your willpower. That's based upon your genes, which you received. And so, your weight, it's similarly based. And if we can use medications to help control weight, cholesterol, blood pressure, blood sugar, let's do that. It's just we live in a time where we're fortunate to have the ability to add medications to help people control health complications including weight. Bob, there are several of the drugs available. How does one think about picking between them? Well, you know, in an ideal medical encounter, the prescriber is going to take into consideration all the factors of prescribing a medication, like any other medication, diabetes, hypertension, you name the condition. Those are things like contraindication to use. What other medical problems does the patient have that may benefit the patient. Patient preferences, of course and side effects, safety, allergies, and then we have cost. And I'll tell you, Kelly, because of our current environment, it's this last factor, cost, that's the most dominant factor when it comes to prescribing medication. I'll have a patient walk in my room, I'll look at the electronic medical record, body mass index, medical problems. I already know in my head what is going to be the most effective medication. That's what we're talking about today. Unfortunately, I then look at the patient insurance, which is also on the electronic medical record, and I see something like Medicaid or Medicare. I already know that it's not going to be covered. It is really quite unfortunate but ideally all these factors go into consideration. Patients often come in and say, I've heard about Ozempic am I a candidate for it, when can I get it? And unfortunately, it's not that simple, of course. And those are types of decisions the prescriber goes through in order to come to a decision, called shared decision making with the patient. Bob, when I asked you the initial question about these drugs, you were mentioning the trade name drugs like Mounjaro and Ozempic and those are made by basically two big pharmaceutical companies, Novo Nordisk and Eli Lilly. But there are compounded versions of these that have hit the scene. Can you explain what that means and what are your thoughts about the use of those medications? So compounding is actually pretty commonly done. It's been approved by the FDA for quite some time. I think most people are familiar with the idea of compounding pharmacies when you have a child that must take a tablet in a liquid form. The pharmacy may compound it to adapt to the child. Or you have an allergy to an ingredient so the pharmacy will compound that same active ingredient so you can take it safely. It's been approved for long periods of time. Anytime a drug is deemed in shortage by the FDA, but in high need by the public, compounding of that trade drug is allowed. And that's exactly what happened with both Semaglutide and Tirzepatide. And of course, that led to this compounding frenzy across the country with telehealth partnering up with different compounding pharmacies. It's basically making this active ingredient. They get a recipe elsewhere, they don't get it from the company, they get this recipe and then they make the drug or compound it themselves, and then they can sell it at a lower cost. I think it's been helpful for people to get the drug at a lower cost. However, buyer beware, because not all compounded pharmacies are the same. The FDA does not closely regulate these compounded pharmacies regarding quality assurance, best practice, and so forth. You have to know where that drug is coming from. Kelly, it's worth noting that just last week, ZepBound and Mounjaro came off the shortage list. You no longer can compound that and I just read in the New York Times today or yesterday that the industry that supports compounding pharmacies is suing the FDA to allow them to continue to compound it. I'm not sure where that's going to go. I mean, Eli Lilly has made this drug. However, Wegovy still is in shortage and that one is still allowed to be compounded. Let's talk a little bit more about costs because this is such a big determinant of whether people use the drugs or not. Bob, you mentioned the high cost, but Tom, how much do the drugs cost and is there any way of predicting what Bob just mentioned with the FDA? If the compounded versions can't be used because there's no longer a shortage, will that decrease pressure on the companies to keep the main drug less expensive. I mean, how do you think that'll all work out? But I guess my main question is how much these things cost and what's covered by insurance? Well first how much do the drugs cost? They cost too much. Semaglutide, known in retail as Wegovy, is $1,300 a month if you do not have insurance that covers it. I believe that Tirzepatide, known as ZepBound, is about $1,000 a month if you don't have insurance that covers that. Both these drugs sometimes have coupons that bring the price down. But still, if you're going to be looking at out of pocket costs of $600 or $700 or $800 a month. Very few people can afford that. The people who most need these medications are people often who are coming from lower incomes. So, in terms of just the future of having these medications be affordable to people, I would hope we're going to see that insurance companies are going to cover them more frequently. I'm really waiting to see if Medicare is going to set the example and say, yes, we will cover these medications for anybody with a BMI of 40 or a BMI of 35 with comorbidities. At this point, Medicare says, we will only pay for this drug if you have a history of heart attack and stroke, because we know the drug is going to improve your life expectancy. But if you don't have that history, you don't qualify. I hope we'll see that. Medicaid actually does cover these medications in some states. It's a state-by-state variation. Short of that, I think we're going to have to have studies showing that people are on these medications for a long time, I mean, three to five years probably will be the window, that they do have a reduction in the expenses for other health expenditures. And as a result, insurers will see, yes, it makes sense to treat excess weight because I can save on the cost of type 2 diabetes or sleep apnea and the like. Some early studies I think that you brought to my attention say the drugs are not cost neutral in the short-term basis of one to two years. I think you're going to have to look longer term. Then I think that there should be competition in the marketplace. As more drugs come online, the drug prices should come down because more will be available. There'll be greater production. Semaglutide, the first drug was $1,300. Zepbound, the second drug Tirzepatide, $1,000. Maybe the third drug will be $800. Maybe the fourth will be $500. And they'll put pressure on each other. But I don't know that to be a fact. That's just my hope. Neither of you as an economist or, nor do you work with the companies that we're talking about. But you mentioned that the high cost puts them out of reach for almost everybody. Why does it make sense for the companies to charge so much then? I mean, wouldn't it make sense to cut the price in half or by two thirds? And then so many more people would use them that the company would up ahead in the long run. Explain that to me. That's what you would think, for sure. And I think that what's happened right now is that is a shortage of these drugs. They cannot produce enough of them. Part of that is the manufacturing of the injector pens that are used to dispense the drug to yourself. I know that Novo Nordisk is building more factories to address this. I assume that Lilly will do the same thing. I hope that over time we will have a larger supply that will allow more people to get on the medication and I hope that the price would come down. Of course, in the U. S. we pay the highest drug prices in the world. Fortunately, given some of the legislation passed, Medicare will be able to negotiate the prices of some of these drugs now. And I think they will negotiate on these drugs, and that would bring prices down across the board. Boy, you know, the companies have to make some pretty interesting decisions, don't they? Because you've alluded to the fact that there are new drugs coming down the road. I'm assuming some of those might be developed and made by companies other than the two that we're talking about. So, so investing in a whole new plant to make more of these things when you've got these competitor drugs coming down the road are some interesting business issues. And that's not really the topic of what we're going to talk about, but it leads to my final question that I wanted to ask both of you. What do you think the future will bring? And what do you see in terms of the pipeline? What will people be doing a year from now or 2 or 5? And, you know, it's hard to have a crystal ball with this, but you two have been, you know, really pioneers and experts on this for many years. You better than anybody probably can answer this question. Bob, let me start with you. What do you think the future will bring? Well, Kelly, I previously mentioned that we finally have this new therapeutic target called the gut brain axis that we didn't know about. And that has really ushered in a whole new range of potential medications. And we're really only at the beginning of this transformation. So not only do we have this GLP 1 and GIP, we have other gut hormones that are also effective not only for weight loss, but other beneficial effects in the body, which will become household names, probably called amylin and glucagon that joins GLP 1. And we not only have these monotherapies like GLP 1 alone, we are now getting triagonists. So, we've got GIP, GLP 1, and glucagon together, which is even amplifying the effect even further. We are also developing oral forms of GLP 1 that in the future you could presumably take a tablet once a day, which will also help bring the cost down significantly and make it more available for individuals. We also have a new generation of medications being developed which is muscle sparing. Tom talked about the importance of being strong and physical function. And with the loss of lean body mass, which occurs with any time you lose weight, you can also lose muscle mass. There's drugs that are also going in that direction. But lastly, let me mention, Kelly, I spend a lot of my time in education. I think the exciting breakthroughs will not be meaningful to the patient unless the professional, the provider and the patient are able to have a nonjudgmental informative discussion during the encounter without stigma, without bias. Talk about the continuum of care available for you, someone living with obesity, and get the medications to the patient. Without that, medications over really sit on the shelf. And we have a lot of more work to do in that area. You know, among the many reasons I admire the both of you is that you've, you've paid a lot of attention to that issue that you just mentioned. You know, what it's like to live with obesity and what people are experiencing and how the stigma and the discrimination can just have devastating consequences. The fact that you're sensitive to those issues and that you're pushing to de-stigmatize these conditions among the general public, but also health care professionals, is really going to be a valuable advance. Thank you for that sensitivity. Tom, what do you think? If you appear into the crystal ball? What does it look like? I would have to agree with Bob that we're going to have so many different medications that we will be able to combine together that we're going to see that it's more than possible to achieve weight losses of 25 to 30 percent of initial body weight. Which is just astonishing to think that pharmaceuticals will be able to achieve what you achieve now with bariatric surgery. I think that it's just, just an extraordinary development. Just so pleased to be able to participate in the development of these drugs at this stage of career. I still see a concern, though, about the stigmatization of weight loss medications. I think we're going to need an enormous dose of medical education to help doctors realize that obesity is a disease. It's a different disease than some of the illnesses that you treat because, yes, it is so influenced by the environment. And if we could change the environment, as you've argued so eloquently, we could control a lot of the cases of overweight and obesity. But we've been unable to control the environment. Now we're taking a course that we have medications to control it. And so, let's use those medications just as we use medications to treat diabetes. We could control diabetes if the food environment was better. A lot of medical education to get doctors on board to say, yes, this is a disease that deserves to be treated with medication they will share that with their patients. They will reassure their patients that the drugs are safe. And that they're going to be safe long term for you to take. And then I hope that society as a whole will pick up that message that, yes, obesity and overweight are diseases that deserve to be treated the same way we treat other chronic illnesses. That's a tall order, but I think we're moving in that direction. BIOS Robert Kushner is Professor of Medicine and Medical Education at Northwestern University Feinberg School of Medicine, and Director of the Center for Lifestyle Medicine in Chicago, IL, USA. After finishing a residency in Internal Medicine at Northwestern University, he went on to complete a post-graduate fellowship in Clinical Nutrition and earned a Master's degree in Clinical Nutrition and Nutritional Biology from the University of Chicago. Dr. Kushner is past-President of The Obesity Society (TOS), the American Society for Parenteral and Enteral Nutrition (ASPEN), the American Board of Physician Nutrition Specialists (ABPNS), past-Chair of the American Board of Obesity Medicine (ABOM), and Co-Editor of Current Obesity Reports. He was awarded the ‘2016 Clinician-of-the-Year Award' by The Obesity Society and John X. Thomas Best Teachers of Feinberg Award at Northwestern University Feinberg School of Medicine in 2017. Dr. Kushner has authored over 250 original articles, reviews, books and book chapters covering medical nutrition, medical nutrition education, and obesity, and is an internationally recognized expert on the care of patients who are overweight or obese. He is author/editor of multiple books including Dr. Kushner's Personality Type Diet (St. Martin's Griffin Press, 2003; iuniverse, 2008), Fitness Unleashed (Three Rivers Press, 2006), Counseling Overweight Adults: The Lifestyle Patterns Approach and Tool Kit (Academy of Nutrition and Dietetics, 2009) and editor of the American Medical Association's (AMA) Assessment and Management of Adult Obesity: A Primer for Physicians (2003). Current books include Practical Manual of Clinical Obesity (Wiley-Blackwell, 2013), Treatment of the Obese Patient, 2nd Edition (Springer, 2014), Nutrition and Bariatric Surgery (CRC Press, 2015), Lifestyle Medicine: A Manual for Clinical Practice (Springer, 2016), and Obesity Medicine, Medical Clinics of North America (Elsevier, 2018). He is author of the upcoming book, Six Factors to Fit: Weight Loss that Works for You! (Academy of Nutrition and Dietetics, December, 2019). Thomas A. Wadden is a clinical psychologist and educator who is known for his research on the treatment of obesity by methods that include lifestyle modification, pharmacotherapy, and bariatric surgery. He is the Albert J. Stunkard Professor of Psychology in Psychiatry at the Perelman School of Medicine at the University of Pennsylvania and former director of the university's Center for Weight and Eating Disorders. He also is visiting professor of psychology at Haverford College. Wadden has published more than 550 peer-reviewed scientific papers and abstracts, as well as 7 edited books. Over the course of his career, he has served on expert panels for the National Institutes of Health, the Federal Trade Commission, the Department of Veterans Affairs, and the U.S. House of Representatives. His research has been recognized by awards from several organizations including the Association for the Advancement of Behavior Therapy and The Obesity Society. Wadden is a fellow of the Academy of Behavioral Medicine Research, the College of Physicians of Philadelphia, the Obesity Society, and Society of Behavioral Medicine. In 2015, the Obesity Society created the Thomas A. Wadden Award for Distinguished Mentorship, recognizing his education of scientists and practitioners in the field of obesity.
Gladiator II co-editor SAM RESTIVO joins "No Script No Problem" to talk about cutting the massive action sequel to the Academy-Award winning film and how he came to collaborate with legendary director RIDLEY SCOTT for the 5th time. Listen as Sam shares intimate details of how he and co-editor Claire Simpson cut critical scenes in the film, working with over 10 cameras on some scenes and heavy VFX at times to bring this epic movie to life. Sam brings us amazing stories from inside the edit bay and on the set of this hit film, which has grossed over $435-million at the global box office so far. In the interview, Sam also explains how he got his start in the industry and worked his way diligently up the Hollywood ladder to be able to edit a blockbusters like Gladiator II and Napoleon. He provides some valuable advice for anyone working their way up in the entertainment industry. Sam and I also discuss the ongoing debate about AI's presence in Hollywood. And lastly, I give you my take on Netflix's foray into broadcasting NFL games on Christmas Day. Thanks for listening! You can also watch on YouTube. Gladiator II Trailer The Berk Report My Instagram Connect with me on Bluesky
In this episode on Speaking Out of Place podcast Professor David Palumbo-Liu talks with Huda Fakhreddine and Anthony Alessandrini about the unique manners in which literature can disclose the human significance of the historical and ongoing genocide in Palestine. Such revelation has to fight at least two things—the sheer brutality and inhumanity of this violence, and the active silencing of Palestinian voices by institutions that, ironically, profess to champion the humanities. Here, once again, we find a pernicious instantiation of the Palestine Exception. Despite these efforts to censor and silence, Huda and Tony delve deeply into the power of Palestinian poetry through translations and readings of some of the most remarkable literature in the world.Anthony Alessandrini teaches English at Kingsborough Community College in Brooklyn and Middle Eastern Studies at the CUNY Graduate Center, where he is also a member of the Committee on Globalization and Social Change. He is the author of Decolonize Multiculturalism and of Frantz Fanon and the Future of Cultural Politics; the editor of Frantz Fanon: Critical Perspectives; and the co-editor of “Resistance Everywhere”: The Gezi Protests and Dissident Visions of Turkey. He has also published a poetry chapbook, Children Imitating Cormorants. He is a Co-Editor of Jadaliyya, is on the Board of Directors of the Middle East Studies Association, is on the faculty of the Brooklyn Institute for Social Research, is a co-convener of the International Solidarity Action Research Network, serves as chair of his union's Academic Freedom Committee, and is a proud member of CUNY Faculty and Staff for Justice in Palestine. Huda J. Fakhreddine is a writer, translator, and Associate Professor of Arabic Literature at the University of Pennsylvania. She is the author of Metapoesis in the Arabic Tradition (Brill, 2015) and The Arabic Prose Poem: Poetic Theory and Practice (Edinburgh University Press, 2021), as well as the co-editor of The Routledge Handbook of Arabic Poetry (Routledge, 2023). Her creative writings include a work of creative nonfiction, Zaman Ṣaghīr Taḥt Shams Thāniya (A Brief Time Under a Different Sun), published by Dar al-Nahda, Beirut, in 2019, and a forthcoming collection Wa Min Thammata al-‘Ālam… (And Then, the World…), to be published by Manshurat Marfa', Beirut, in 2025. She serves as co-editor of Middle Eastern Literatures and as an editor for the Library of Arabic Literature.www.palumbo-liu.comhttps://speakingoutofplace.comBluesky @palumboliu.bsky.socialInstagram @speaking_out_of_place
In this episode on Speaking Out of Place podcast Professor David Palumbo-Liu talks with Huda Fakhreddine and Anthony Alessandrini about the unique manners in which literature can disclose the human significance of the historical and ongoing genocide in Palestine. Such revelation has to fight at least two things—the sheer brutality and inhumanity of this violence, and the active silencing of Palestinian voices by institutions that, ironically, profess to champion the humanities. Here, once again, we find a pernicious instantiation of the Palestine Exception. Despite these efforts to censor and silence, Huda and Tony delve deeply into the power of Palestinian poetry through translations and readings of some of the most remarkable literature in the world.Anthony Alessandrini teaches English at Kingsborough Community College in Brooklyn and Middle Eastern Studies at the CUNY Graduate Center, where he is also a member of the Committee on Globalization and Social Change. He is the author of Decolonize Multiculturalism and of Frantz Fanon and the Future of Cultural Politics; the editor of Frantz Fanon: Critical Perspectives; and the co-editor of “Resistance Everywhere”: The Gezi Protests and Dissident Visions of Turkey. He has also published a poetry chapbook, Children Imitating Cormorants. He is a Co-Editor of Jadaliyya, is on the Board of Directors of the Middle East Studies Association, is on the faculty of the Brooklyn Institute for Social Research, is a co-convener of the International Solidarity Action Research Network, serves as chair of his union's Academic Freedom Committee, and is a proud member of CUNY Faculty and Staff for Justice in Palestine. Huda J. Fakhreddine is a writer, translator, and Associate Professor of Arabic Literature at the University of Pennsylvania. She is the author of Metapoesis in the Arabic Tradition (Brill, 2015) and The Arabic Prose Poem: Poetic Theory and Practice (Edinburgh University Press, 2021), as well as the co-editor of The Routledge Handbook of Arabic Poetry (Routledge, 2023). Her creative writings include a work of creative nonfiction, Zaman Ṣaghīr Taḥt Shams Thāniya (A Brief Time Under a Different Sun), published by Dar al-Nahda, Beirut, in 2019, and a forthcoming collection Wa Min Thammata al-‘Ālam… (And Then, the World…), to be published by Manshurat Marfa', Beirut, in 2025. She serves as co-editor of Middle Eastern Literatures and as an editor for the Library of Arabic Literature.www.palumbo-liu.comhttps://speakingoutofplace.comBluesky @palumboliu.bsky.socialInstagram @speaking_out_of_place
In this episode on Speaking Out of Place podcast Professor David Palumbo-Liu talks with Huda Fakhreddine and Anthony Alessandrini about the unique manners in which literature can disclose the human significance of the historical and ongoing genocide in Palestine. Such revelation has to fight at least two things—the sheer brutality and inhumanity of this violence, and the active silencing of Palestinian voices by institutions that, ironically, profess to champion the humanities. Here, once again, we find a pernicious instantiation of the Palestine Exception. Despite these efforts to censor and silence, Huda and Tony delve deeply into the power of Palestinian poetry through translations and readings of some of the most remarkable literature in the world.Anthony Alessandrini teaches English at Kingsborough Community College in Brooklyn and Middle Eastern Studies at the CUNY Graduate Center, where he is also a member of the Committee on Globalization and Social Change. He is the author of Decolonize Multiculturalism and of Frantz Fanon and the Future of Cultural Politics; the editor of Frantz Fanon: Critical Perspectives; and the co-editor of “Resistance Everywhere”: The Gezi Protests and Dissident Visions of Turkey. He has also published a poetry chapbook, Children Imitating Cormorants. He is a Co-Editor of Jadaliyya, is on the Board of Directors of the Middle East Studies Association, is on the faculty of the Brooklyn Institute for Social Research, is a co-convener of the International Solidarity Action Research Network, serves as chair of his union's Academic Freedom Committee, and is a proud member of CUNY Faculty and Staff for Justice in Palestine. Huda J. Fakhreddine is a writer, translator, and Associate Professor of Arabic Literature at the University of Pennsylvania. She is the author of Metapoesis in the Arabic Tradition (Brill, 2015) and The Arabic Prose Poem: Poetic Theory and Practice (Edinburgh University Press, 2021), as well as the co-editor of The Routledge Handbook of Arabic Poetry (Routledge, 2023). Her creative writings include a work of creative nonfiction, Zaman Ṣaghīr Taḥt Shams Thāniya (A Brief Time Under a Different Sun), published by Dar al-Nahda, Beirut, in 2019, and a forthcoming collection Wa Min Thammata al-‘Ālam… (And Then, the World…), to be published by Manshurat Marfa', Beirut, in 2025. She serves as co-editor of Middle Eastern Literatures and as an editor for the Library of Arabic Literature.www.palumbo-liu.comhttps://speakingoutofplace.comBluesky @palumboliu.bsky.socialInstagram @speaking_out_of_place
Today on Speaking Out of Place I am honored to welcome Huda Fakhreddine and Anthony Alessandrini to talk about the unique manners in which literature can disclose the human significance of the historical and ongoing genocide in Palestine. Such revelation has to fight at least two things—the sheer brutality and inhumanity of this violence, and the active silencing of Palestinian voices by institutions that, ironically, profess to champion the humanities. Here, once again, we find a pernicious instantiation of the Palestine Exception. Despite these efforts to censor and silence, Huda and Tony delve deeply into the power of Palestinian poetry, through translations and readings of some of the most remarkable literature in the world. Anthony Alessandrini teaches English at Kingsborough Community College in Brooklyn and Middle Eastern Studies at the CUNY Graduate Center, where he is also a member of the Committee on Globalization and Social Change. He is the author of Decolonize Multiculturalism and of Frantz Fanon and the Future of Cultural Politics; the editor of Frantz Fanon: Critical Perspectives; and the co-editor of “Resistance Everywhere”: The Gezi Protests and Dissident Visions of Turkey. He has also published a poetry chapbook, Children Imitating Cormorants. He is a Co-Editor of Jadaliyya, is on the Board of Directors of the Middle East Studies Association, is on the faculty of the Brooklyn Institute for Social Research, is a co-convener of the International Solidarity Action Research Network, serves as chair of his union's Academic Freedom Committee, and is a proud member of CUNY Faculty and Staff for Justice in Palestine. Huda J. Fakhreddine is a writer, translator, and Associate Professor of Arabic Literature at the University of Pennsylvania. She is the author of Metapoesis in the Arabic Tradition (Brill, 2015) and The Arabic Prose Poem: Poetic Theory and Practice (Edinburgh University Press, 2021), as well as the co-editor of The Routledge Handbook of Arabic Poetry (Routledge, 2023). Her creative writings include a work of creative nonfiction, Zaman Ṣaghīr Taḥt Shams Thāniya (A Brief Time Under a Different Sun), published by Dar al-Nahda, Beirut, in 2019, and a forthcoming collection Wa Min Thammata al-‘Ālam… (And Then, the World…), to be published by Manshurat Marfa', Beirut, in 2025. She serves as co-editor of Middle Eastern Literatures and as an editor for the Library of Arabic Literature.
In this segment of The Mark Reardon Show, Mark is joined by Garret Price, the Director and Co-Editor of "Yacht Rock: A Dockumentary", an HBO Original airing on MAX. They discuss the many aspect of the documentary and how it all came together.
In hour 3 of The Mark Reardon Show, Mark is joined by In this segment of The Mark Reardon Show, Mark is joined by Phil Holloway, a FOX News Legal Analyst and former Assistant District Attorney and Former Police Officer. They discuss the latest update from the jury in the Daniel Penny trial. He is then joined by Garret Price, the Director and Co-Editor of "Yacht Rock: A Dockumentary", an HBO Original airing on MAX. They discuss the many aspect of the documentary and how it all came together. Mark wraps up the show with The Audio Cut of the Day.
In hour 1 of The Mark Reardon Show, Mark is joined by the Reardon Roundtable which includes Jane Dueker, John Lamping, and John Gaskin. They discuss the latest in the Daniel Penny trial, Biden pardoning Hunter, STL politics, and more. In hour 2, Ethan hosts, "Ethan's News" in place of Sue. They discuss Joe Burrow's latest crazy purchase, the latest music anniversaries and birthday's, and the random fact of the day. Mark is then joined by Paul Hall with Common Guy's Film Reviews. They discuss the latest trending movies and shows including "The Order", "Nightbitch", "The Madness", and more. He is then joined by KSDK Sports Director Frank Cusumano who previews Mizzou vs Kansas basketball this weekend, Mizzou Football's big National Signing Day, the Blues recent hot stretch, and more. In hour 3, Mark is joined by In this segment of The Mark Reardon Show, Mark is joined by Phil Holloway, a FOX News Legal Analyst and former Assistant District Attorney and Former Police Officer. They discuss the latest update from the jury in the Daniel Penny trial. He is then joined by Garret Price, the Director and Co-Editor of "Yacht Rock: A Dockumentary", an HBO Original airing on MAX. They discuss the many aspect of the documentary and how it all came together. Mark wraps up the show with The Audio Cut of the Day.
A football coach has found herself in a legal row with a sport governing body over expenses.She claims that spaghetti and chopped tomatoes are “culturally” African ingredients. Is she right? Do foods have a strict nationality?Joining Seán to discuss is Dr Máirtín Mac Con Iomair, Chair of the Masters in Gastronomy and Food Studies at TU Dublin and Co-Editor of ‘Irish Food History: A Companion'.
Join Kenny and Max as we review and tier list over 20 movies we've seen with our Ohana movie club! Which of us has the best tastes in movies (according to us at least), and who do YOU think has picked the best string of films? —————
Newsroom won't say why an investigative journalist was initially barred from tomorrow's state apology to survivors of Abuse in Care. Speaker Gerry Brownlee initially declined Aaron Smale's accreditation application, citing undisclosed issues with his conduct on a prior occasion. But after pressure, Brownlee has allowed Smale to attend, if accompanied by a Newsroom journalist. Co-editor Mark Jennings says Brownlee probably didn't have the full story. "He hadn't witnessed any of it himself, he hadn't reviewed any tapes - he was going on the say of other people." LISTEN ABOVESee omnystudio.com/listener for privacy information.
For NSP 61 we spoke with Christopher Coyne about the economics or warmaking. We also discussed the boomerang effect, pacifism, revolution, and libertarian anarchism. Christopher J. Coyne is a Professor of Economics at George Mason University, the Associate Director of the F. A. Hayek Program for Advanced Study in Philosophy, Politics, and Economics at the Mercatus Center, and the Director of the Initiative for the Study of a Stable Peace (ISSP) through the Hayek Program. He is also a Senior Fellow at the Independent Institute and a Non-resident Fellow at the Quincy Institute. Coyne serves as the Co-Editor of The Review of Austrian Economics and of The Independent Review. Chris is the editor of The Legacy of Robert Higgs (2024, Mercatus Center), and the author or co-author of How to Run Wars: A Confidential Playbook for the National Security Elite (2024, Independent Institute), In Search of Monsters to Destroy: The Folly of American Empire and the Paths to Peace (2022, Independent Institute), Manufacturing Militarism: U.S. Government Propaganda in the War on Terror (2021, Stanford University Press), Tyranny Comes Home: The Domestic Fate of U.S. Militarism (2018, Stanford University Press), and many more. Links: Initiative for the Study of a Stable Peace https://www.stablepeace.com F. A. Hayek Program https://www.mercatus.org/hayekprogram How To Run Wars book https://www.independent.org/store/book.asp?id=145 The Legacy of Robert Higgs book https://www.mercatus.org/hayekprogram/research/books/legacy-robert-higgs Thanks for listening! Please like, comment, subscribe, and share! --- If you'd like to see more anarchist and anti-authoritarian interviews, please consider supporting this project financially by becoming a patron at https://www.patreon.com/nonserviammedia Follow Non Serviam Media Collective on: Mastodon https://kolektiva.social/@nonserviammedia Bluesky https://bsky.app/profile/nonserviammedia.bsky.social As well as Facebook, Instagram, Threads, and X/Twitter. Connect with Lucy Steigerwald via: https://mastodon.social/@LucyStag https://bsky.app/profile/lucystag.bsky.social https://x.com/LucyStag https://lucysteigerwald.substack.com/
Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about Kamala Harris' latest unconstitutional bribe to attract black voters. For more coverage on the issues that matter to you visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
10/15/24 Hour 3 Vince speaks with Jason Miyares, Attorney General of the Commonwealth of Virginia about the DOJ suing the Commonwealth to allow non-citizens to vote. Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about Kamala Harris' latest unconstitutional bribe to attract black voters. For more coverage on the issues that matter to you visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
In this episode of Occupied Thoughts, FMEP President Lara Friedman speaks with Mouin Rabbani about Israel's war on Gaza, its offensive in Lebanon, and how these and other developments fit into Israel's broader objectives in the region, most notably with respect to Iran. Mouin is widely published analyst and commentator on Palestinian affairs, the Israeli-Palestinian conflict, and the contemporary Middle East. He was previously Senior Analyst Middle East and Special Advisor on Israel-Palestine with the International Crisis Group, and head of political affairs with the Office of the United Nations Special Envoy for Syria. He is Co-Editor of Jadaliyya E-zine. Show notes: https://fmep.org/resource/conversation-with-mouin-rabbani/
Pam insightfully reveals how God is orchestrating all world events according to His plan for world transition. Guest Steve Groves of the Heritage Foundation explains how Project 2025 is a guide for transition for the next conservative U.S. President.Faith to Live By is recognized By Feedspot as among the top 15 Charismatic Christian Podcasts: https://blog.feedspot.com/charismatic_christian_podcasts/SHOW NOTES – Partial, view complete Show Notes Here.CONNECT WITH TODAY'S GUEST: Steve Groves Steven Groves works to protect and preserve American sovereignty, self-governance, and independence as the Margaret Thatcher Fellow in Heritage's Margaret Thatcher Center for Freedom. He is the Co-Editor of Mandate for Leadership: The Conservative Promise, the flagship policy book for the 2025 Presidential Transition Project.From 2017-2020, Groves served in the Trump Administration in several roles, first as Ambassador Nikki Haley's Chief of Staff at the U.S. Mission to the United Nations. Groves subsequently joined the White House where he was commissioned as Special Assistant to the President and Assistant Special Counsel, representing the White House in the investigation conducted by Robert Mueller into Russian attempts to interfere in the 2016 election. After the conclusion of the investigation, Groves continued to serve at the White House as Deputy Press Secretary.See complete bio and accomplishments here: https://www.heritage.org/staff/steven-grovesLINKS FROM SHOW CONTENT: Barry Wunsch prophecies: https://rumble.com/v5gfrh5-barry-wunsch-october-is-going-to-run-hot.html?e9s=src_v1_ucpAmir Tsarfati's report: https://t.me/beholdisraelchannelProject 2025 Website: https://www.project2025.org/ FOR FURTHER STUDY: Stay informed and involved. Support Heritage Action Group: https://donate.heritageaction.com/action-eme03438 ACTION STEPS:Share this podcast with any and everyone you know: https://media.rss.com/faithtoliveby/feed.xmlLook into Pam's online apologetics class: https://pamelachristianministries.com/faith-to-live-by-training-center SUPPORT:Affiliate Sponsors Main Page: https://pamelachristianministries.com/affiliate-sponsors-and-partners
Today's episode of The Nonprofit Build Up Podcast is part 2 of our deep dive into "Transformative Philanthropy" with Dr. Aleesha Taylor, founder of Herald Advisors. Dr. Taylor passionately shares how Herald Advisors was born from her relentless drive to create real, lasting change in communities.In this episode, she breaks down the intricate challenges of philanthropic funding, internal power structures, and the bold, systems-level shifts needed to achieve meaningful impact. If you're serious about driving systems change, strategic philanthropy, and effective nonprofit leadership, this episode is essential listening.Dr. Taylor's insights will push you to think critically about how we can truly support communities with accountable, authentic, and impactful philanthropy.Dr. Aleesha Taylor, Principal, Herald AdvisorsDr. Aleesha Taylor is passionate about marshaling resources to benefit vulnerable communities and address pervasive social problems. She has over 20 years of experience leading at the intersection of education, philanthropy, and international development. Aleesha is the Founder and Chief Strategist of Herald Advisors, a boutique strategic advisory firm that helps clients maximize their impact through thought partnership, organizational capacity building, program and strategy design, and leadership and team development. Herald Advisors works with a global range of philanthropies, nonprofit organizations, and networks to strengthen teams and programs and develop sound fundraising and partnership strategies. Sample clients and projects include:Gender at the Center Initiative: Designed partnership and governance arrangements for the multistakeholder initiative to advance gender equality across eight African countries.Lever for Change: Impact Partner leading efforts to strengthen diversity, equity, inclusion, and justice across finalists' proposals for awards ranging from five to one hundred million (USD).Education.org (formerly Insights for Education): Served as Interim Chief Technical Officer, establishing MOUs with the Government of Kenya and USAID and designing national and global strategies to increase the availability and use of relevant data for decision-making.Chemonics: Provides design and implementation support for USAID-funded education projects.Comic Relief-US: Positioned entity to leverage $23 million investment from Salesforce for global programs that address intergenerational poverty.She is the former Deputy Director of the Open Society Foundations' global education program, where she managed a team across five countries to implement a global grantmaking portfolio and advanced priorities and partnerships on behalf of the foundations' Chairman and President. Aleesha was central to the creation of the Private Sector/Foundations constituency of the Global Partnership for Education's Board of Directors and served as its representative on the Board's Financial Advisory Committee, which channeled $1.2 billion in grant funding to developing country governments during her tenure.Aleesha was a Lecturer in International Educational Development at Columbia University's Teachers College, where she also completed her doctoral studies. She also holds degrees in psychology from Spelman College and the Graduate Faculty for Political and Social Sciences of the New School for Social Research. She has written numerous articles and chapters and is the Co-Editor of Partnership Paradox: The Post-Conflict Reconstruction of Liberia's Education System, Foreword by President Ellen Johnson Sirleaf.
Today's Non Profit Build Up podcast episode is an insightful conversation with Dr. Aleesha Taylor, a leading voice in philanthropy and nonprofit leadership. We delve into the transformative work being led by Dr. Taylor, with a spotlight on Herald Advisors, a firm she founded after her impactful tenure at the Open Society Foundations.In this episode, Dr. Taylor shares the genesis of Herald Advisors and how it emerged from her deep desire to facilitate initiatives that profoundly impact communities. We discuss the complex interplay of philanthropic funds, the power dynamics within organizations, and the systems-level changes needed to truly effect lasting impact.This episode is a must-listen for anyone interested in systems change, strategic philanthropy, and the intricacies of nonprofit leadership. Dr. Taylor's insights challenge us to think critically about how we can better support communities through authentic, accountable, and impactful philanthropy.Don't miss this conversation that will inspire you to reconsider how you engage with the sector.
Christopher G. Byers, DVM, DACVECC, DACVIM (SAIM), CVJ, is a practicing board-certified veterinary emergency & critical care and small animal internal medicine specialist, as well as a certified veterinary journalist, based in Omaha, Nebraska. He received his Bachelor of Science degree as a University Honors Scholar in Animal Sciences from Colorado State University and his Doctor of Veterinary Medicine from Cornell University. He is the Co-Editor of the textbooks, Feline Emergency & Critical Care Medicine and Canine Emergency & Critical Care Medicine. He has also published chapters and articles in numerous textbooks and peer-reviewed medical journals.
Effective altruism is a philosophical and social movement that uses empirical data to maximize the impact of charitable efforts. Those who champion EA praise its methodological framework for maximizing the effectiveness of donations, thus ensuring equal consideration for all individuals. Those who challenge EA argue that its emphasis on measurable outcomes may overlook important yet hard-to-quantify causes, potentially restricting the scope of what's considered beneficial. Now we debate: Does the Effective Altruism Movement Get Giving Right? Arguing Yes: Peter Singer, Author of “The Most Good You Can Do”; Philosopher and Professor Emeritus of Bioethics at the University Center for Human Values at Princeton University Arguing No: Alice Crary, Co-Editor of “The Good it Promises, The Harm it Does: Critical Essays on Effective Altruism”; University Distinguished Professor of Philosophy at The New School for Social Research Emmy award-winning journalist John Donvan moderates Learn more about your ad choices. Visit podcastchoices.com/adchoices
To many, we're living through a golden age of TV. But behind the rich offerings for consumers lie several growing structural issues, from a market oversupplied by streamers desperate for subscriptions, to the consequences of the US actors and writers strike, to a downturn in the advertising spend that powers the UK industry. Ros talks to a panel of TV big hitters at the Edinburgh International TV Festival. We hear from the Democratic National Convention where Kamala Harris is about to accept her party's nomination for President - all at a time when the candidate is refusing to do media interviews. Plus, after a spate of newspaper closures and high profile resignations, we explore the state of Scottish news media during a tumultuous period in the nation's politics. Guests: Chris Curtis, Editor, Broadcast; Stephen Lambert, Chief Executive, Studio Lambert, Andy Harries, CEO, Left Bank Pictures; Claire Lundberg, founder, CTL Scouting; Nicola Shindler, Chief Executive, Quay Street Productions Douglas Fraser, Business and Economy Editor, BBC Scotland; Frank O'Donnell, Senior Partner at Charlotte Street Partners; Karin Goodwin, Co-Editor, The Ferret; Nayeema Raza, Co-Presenter, Mixed Signals Presenter: Ros Atkins Producer: Simon Richardson Assistant Producer: Lucy Wai
"I think the negativity is way overblown. Americans expect more than they actually deserve,” says Brent Cook, Co-Editor of Exploration Insights. He tells Daniela Cambone that the habit of overspending contributes to the financial hardship many Americans are experiencing, especially with inflation. Questions on Protecting Your Wealth with Gold & Silver? Schedule a Strategy Call Here ➡️ https://calendly.com/itmtrading/podcast or Call 866-349-3310
Kieran speaks to Southend United chief executive Tom Lawrence, and co-editor of Southend Fanzine, All At Sea, Liam Ager, about the recent takeover of the club by a consortium led by Australian businessman Justin Rees. Follow Kevin on X - @kevinhunterday Follow Kieran on X - @KieranMaguire Follow Producer Guy on X - @guykilty Follow The Price of Football on X - @pof_pod Send in a question: questions@priceoffootball.com Support The Price of Football on Patreon: https://www.patreon.com/priceoffootball Check out the Price of Football merchandise store: https://the-price-of-football.backstreetmerch.com/ Visit the website: https://priceoffootball.com/ For sponsorship email - info@adelicious.fm The Price of Football is a Dap Dip production: https://dapdip.co.uk/ contact@dapdip.co.uk Learn more about your ad choices. Visit podcastchoices.com/adchoices
Join Kenny, Kyle, and Max as we discuss the board games and movies that we consider the ultimate DIScomfort. These games and movies are disturbing, anxiety inducing, or whatever the reason, they make us UNCOMFORTABLE. Which, can be good or bad. —————
Scott Lucas https://x.com/ScottLucas_EA Scott Lucas is a political analyst with more than 30 years' experience including a wide range of interests from academic expertise to journalism, and public media, as well as digital engagement. Scott is a regular contributor to international TV, radio, and digital outlets. He is a Professor at the Clinton Institute, University College Dublin, and Professor Emeritus at the University of Birmingham. ---------- James Ker-Lindsay Professor James Ker-Lindsay is an academic and analyst with internationally recognised expertise on Southeast Europe (Balkans, Turkey, Greece, and Cyprus). He has extensive experience working in Government, Private Sector, Higher Education, and Think Tanks. He is a regular commentator for the international media, including BBC, CNN and Reuters and was formerly Co-Editor of the Cyprus Review. ---------- Pyotr Kurzin Pyotr Kurzin is a commentator and YouTube host on the subjects of geopolitical risk, global macroeconomics and current affairs. Half British and half Russian, he is a product of the Cold War, and endlessly curious about why the world is the wat it is. He hosts contrasting conversations with diverse guests, often with contrasting perspectives and expertise, to help audiences become more informed. ---------- SUPPORT THE CHANNEL: https://www.buymeacoffee.com/siliconcurtain https://www.patreon.com/siliconcurtain ---------- TRUSTED CHARITIES ON THE GROUND: kharpp - Reconstruction project supporting communities in Kharkiv and Przemysl https://kharpp.com/ Save Ukraine https://www.saveukraineua.org/ Superhumans - Hospital for war traumas https://superhumans.com/en/ UNBROKEN - Treatment. Prosthesis. Rehabilitation for Ukrainians in Ukraine https://unbroken.org.ua/ Come Back Alive https://savelife.in.ua/en/ Chefs For Ukraine - World Central Kitchen https://wck.org/relief/activation-chefs-for-ukraine Ukrainian Freedom News https://www.ukrainianfreedomnews.com/donation/ UNITED24 - An initiative of President Zelenskyy https://u24.gov.ua/ Serhiy Prytula Charity Foundation https://prytulafoundation.org NGO “Herojam Slava” https://heroiamslava.org/ NOR DOG Animal Rescue https://www.nor-dog.org/home/ ---------- PLATFORMS: Twitter: https://twitter.com/CurtainSilicon Instagram: https://www.instagram.com/siliconcurtain/ Podcast: https://open.spotify.com/show/4thRZj6NO7y93zG11JMtqm Linkedin: https://www.linkedin.com/in/finkjonathan/ Patreon: https://www.patreon.com/siliconcurtain ---------- Welcome to the Silicon Curtain podcast. Please like and subscribe if you like the content we produce. It will really help to increase the popularity of our content in YouTube's algorithm. Our material is now being made available on popular podcasting platforms as well, such as Spotify and Apple Podcasts.
Join Kenny and Max as we discuss the board games and movies that we consider the ultimate comfort. Whether all is right in the world, it's cozy, or whatever reason we choose, THESE are our favorites. —————
Rankings are so fun. Join Max, Kyle, and Kenny as we talk the board games we've been playing, the movies we've been watching, and RANKINGS! We rank cereal, movie monsters, pokemon, board game box art, video games, musicians, and more! —————
6/25/24 Hour 2 Vince takes listeners calls about predictions for the upcoming debate. Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about the left's latest attempt to smear Justice Clarence Thomas as an unethical Justice. For more coverage on the issues that matter to you visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about the left's latest attempt to smear Justice Clarence Thomas as an unethical Justice. For more coverage on the issues that matter to you visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
Craig is joined by Ethan Fisher @efisher330-Co-Editor and Site Expert for Rumbunter-to discuss the polar opposite performances we have seen from the Pirates at times, the fact that they are still hovering around .500, the effect that injuries have had on the team thus far this season, how the team can improve and the areas they could and/or should add. Bought to you by VOUCH. Visit the Bucs In The Basement VOUCH Store to support great small businesses vouched for by us! Craig Toth previously covered the Pirates for Inside The Bucs Basement, but now simply joins his buddy Chris at a 9-foot homemade oak bar every week to talk Pittsburgh Pirates Baseball. Listen. Subscribe. Share. We are "For Fans, By Fans & All Pirates Talk." THE Pirates Fan Podcast found EVERYWHERE podcasts can be found and always at BucsInTheBasement.com!
"McElroy & Cubelic In The Morning" airs 7am-10am weekdays on WJOX-94.5!!See omnystudio.com/listener for privacy information.
5/23/24 Hour 1 The NY Times gins up another “controversy,” this time over Sam Alito flying a religious flag outside his NJ beach home. Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about Justice Alito flying “An Appeal to Heaven” flag outside his beach home, and the left thinking this is a scandal. For more coverage on the issues that matter to you visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
Vince speaks with Mark Paoletta, Senior Fellow at the Center For Renewing America, and Co-Editor of the book “Created Equal: Clarence Thomas in His Own Words” about Justice Alito flying “An Appeal to Heaven” flag outside his beach home and the left thinking this is a scandal. For more coverage on the issues that matter to you visit www.WMAL.com, download the WMAL app or tune in live on WMAL-FM 105.9 from 3-6pm. To join the conversation, check us out on social media: @WMAL @VinceCoglianese. Executive Producer: Corey Inganamort @TheBirdWords See omnystudio.com/listener for privacy information.
© 2020-2025 Ivy Podcast Discovery LLC
